바이오시뮬레이션 시장 규모, 점유율, 동향 분석 보고서 : 제품별, 용도별, 치료 분야별, 전개 모델별, 가격 모델별, 최종 용도별, 지역별, 부문별 예측(2025-2030년)

Biosimulation Market Growth & Trends:

The global biosimulation market size is expected to reach USD 10.0 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 17.0% from 2025 to 2030. The key factors fueling the market growth include the increasing incidence of chronic diseases, increase in healthcare digitization, and usage of biosimulation solutions in clinical trials and research.

The need for drug discovery and development amidst the prevalence of acute and chronic diseases has increased the allocation of funds for R&D activities, which has propelled the adoption of biosimulation solutions. In addition, a high drug attrition rate leads to an increase in the cost of clinical trials, which is expected to drive the clinical urgency to incorporate in silico biology approach. This approach significantly reduces the probability of drug failure by predicting biological interactions, thereby reducing overall costs.

A rise in drug relapse rates, drug resistance cases, and the limited availability of drugs to treat diseases such as AIDS have led to high clinical urgency for the adoption of biosimulation in applications such as drug development and drug discovery.

The COVID-19 pandemic also had a significant impact on the market growth. Simulations Plus, for instance, launched the StrategiesPlus COVID-19 ACT Program in March 2020 for speeding consulting assistance to any organization involved in COVID-19 research. The company declared that as of November 2020, its business was not materially adversely affected. However, the continuing spread of COVID-19 and the measures taken by governments of affected countries are likely to disrupt the supply chain and adversely impact its business and financial performance.

Surging demand for biosimulation software and services can also be attributed to their higher cost-efficiency. Biosimulation solutions enable cost-effective prediction of toxicity, adverse reactions, and efficacy of investigational drugs during the early stages of product development, thus limiting the probability of drug relapse and adverse events at later stages.

Market players are investing in many strategic initiatives, such as acquisitions, mergers, partnerships, and product launches, to maintain a competitive edge in the market. For instance, in January 2022, Simulations Plus Inc. collaborated with an animal health company for validating current animal physiologically based pharmacokinetic (PBPK) models. With this funded collaboration, the company aimed to add a critical new species to its GastroPlus platform. Moreover, in November 2021, Yokogawa Electric Corporation acquired Insilico Biotechnology AG, a Germany-based company that develops and provides bioprocess software and services.

Biosimulation Market Report Highlights:

• Software dominated the market, with a revenue share of 62.02% in 2024. This can be attributed to the availability of application-specific software catering to specific research and development requirements.
• The drug development segment held the largest market share of 55.43% in 2024, driven by the increasing number of drug development processes.
• Oncology held the largest revenue share in 2024. In oncology, biosimulation is crucial in understanding tumor dynamics, treatment responses, and patient-specific factors influencing cancer outcomes.
• Cloud-based deployment model dominated the market and held the largest revenue share of over 43.00% in 2024 and is expected to grow at the fastest CAGR during the forecast period.
• License-based model held the largest revenue share in 2024. The advantage of this model is that it provides users with access to sophisticated tools without the need for substantial investments in infrastructure or development.
• Life science companies accounted for the largest revenue share in 2024. These companies are increasingly adopting biosimulation software as a critical tool in drug development and research.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Market Definitions
  • 1.2.1. Product Segment
  • 1.2.2. Application Segment
  • 1.2.3. Therapeutic Area Segment
  • 1.2.4. Deployment Model Segment
  • 1.2.5. Pricing Model Segment
  • 1.2.6. End Use Segment
• 1.3. Information analysis
  • 1.3.1. Market formulation & data visualization
• 1.4. Data validation & publishing
• 1.5. Information Procurement
  • 1.5.1. Primary Research
• 1.6. Information or Data Analysis
• 1.7. Market Formulation & Validation
• 1.8. Market Model
• 1.9. Total Market: CAGR Calculation
• 1.10. Objectives
  • 1.10.1. Objective 1
  • 1.10.2. Objective 2

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Snapshot
• 2.3. Competitive Insights Landscape

Chapter 3. Biosimulation Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook.
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Rising prevalence of chronic diseases
    • 3.2.1.2. Growing demand for personalized medicine
    • 3.2.1.3. Technological advancements
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. High cost associated with biosimulation technology and software
    • 3.2.2.2. Stringent regulatory requirements
• 3.3. Biosimulation Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Technological landscape
    • 3.3.2.3. Economic landscape
    • 3.3.2.4. Environmental Landscape
    • 3.3.2.5. Legal Landscape
    • 3.3.2.6. Social Landscape
• 3.4. COVID-19 Impact Analysis

Chapter 4. Biosimulation Market: Product Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. Global Biosimulation Market Product Movement Analysis
• 4.3. Global Biosimulation Market Size & Trend Analysis, by Product, 2018 - 2030 (USD Million)
• 4.4. Software
  • 4.4.1. Market estimates and forecasts 2018 - 2030 (USD Million)
  • 4.4.2. Molecular Modeling & Simulation Software
    • 4.4.2.1. Market estimates and forecasts 2018 - 2030 (USD Million)
  • 4.4.3. Clinical Trial Design Software
    • 4.4.3.1. Market estimates and forecasts 2018 - 2030 (USD Million)
  • 4.4.4. PK/PD Modeling and Simulation Software
    • 4.4.4.1. Market estimates and forecasts 2018 - 2030 (USD Million)
  • 4.4.5. Pbpk Modeling and Simulation Software
    • 4.4.5.1. Market estimates and forecasts 2018 - 2030 (USD Million)
  • 4.4.6. Toxicity Prediction Software
    • 4.4.6.1. Market estimates and forecasts 2018 - 2030 (USD Million)
  • 4.4.7. Other Software
    • 4.4.7.1. Market estimates and forecasts 2018 - 2030 (USD Million)
• 4.5. Services
  • 4.5.1. Market estimates and forecasts 2018 - 2030 (USD Million)
  • 4.5.2. Contract Services
    • 4.5.2.1. Market estimates and forecasts 2018 - 2030 (USD Million)
  • 4.5.3. Consulting
    • 4.5.3.1. Market estimates and forecasts 2018 - 2030 (USD Million)
  • 4.5.4. Other (Implementation, Training, & Support, etc.)
    • 4.5.4.1. Market estimates and forecasts 2018 - 2030 (USD Million)

Chapter 5. Biosimulation Market: Application Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. Global Biosimulation Market Application Movement Analysis
• 5.3. Global Biosimulation Market Size & Trend Analysis, by Application, 2018 - 2030 (USD Million)
• 5.4. Drug Discovery & Development
  • 5.4.1. Market estimates and forecasts 2018 - 2030 (USD Million)
• 5.5. Disease Modeling
  • 5.5.1. Market estimates and forecasts 2018 - 2030 (USD Million)
• 5.6. Other (Precision Medicine, Toxicology, etc.)
  • 5.6.1. Market estimates and forecasts 2018 - 2030 (USD Million)

Chapter 6. Biosimulation Market: Therapeutic Area Estimates & Trend Analysis

• 6.1. Segment Dashboard
• 6.2. Global Biosimulation Market Therapeutic Area Movement Analysis
• 6.3. Global Biosimulation Market Size & Trend Analysis, by Therapeutic Area, 2018 - 2030 (USD Million)
• 6.4. Oncology
  • 6.4.1. Market estimates and forecasts 2018 - 2030 (USD Million)
• 6.5. Cardiovascular Disease
  • 6.5.1. Market estimates and forecasts 2018 - 2030 (USD Million)
• 6.6. Infectious Disease
  • 6.6.1. Market estimates and forecasts 2018 - 2030 (USD Million)
• 6.7. Neurological Disorders
  • 6.7.1. Market estimates and forecasts 2018 - 2030 (USD Million)
• 6.8. Others
  • 6.8.1. Market estimates and forecasts 2018 - 2030 (USD Million)

Chapter 7. Biosimulation Market: Deployment Model Estimates & Trend Analysis

• 7.1. Segment Dashboard
• 7.2. Global Biosimulation Market Deployment Model Movement Analysis
• 7.3. Global Biosimulation Market Size & Trend Analysis, by Deployment Model, 2018 - 2030 (USD Million)
• 7.4. Cloud-based
  • 7.4.1. Market estimates and forecasts 2018 - 2030 (USD Million)
• 7.5. On-premises
  • 7.5.1. Market estimates and forecasts 2018 - 2030 (USD Million)
• 7.6. Hybrid Model
  • 7.6.1. Market estimates and forecasts 2018 - 2030 (USD Million)

Chapter 8. Biosimulation Market: Pricing Model Estimates & Trend Analysis

• 8.1. Segment Dashboard
• 8.2. Global Biosimulation Market Pricing Model Movement Analysis
• 8.3. Global Biosimulation Market Size & Trend Analysis, by Pricing Model, 2018 - 2030 (USD Million)
• 8.4. License-based Model
  • 8.4.1. Market estimates and forecasts 2018 - 2030 (USD Million)
• 8.5. Subscription-based Model
  • 8.5.1. Market estimates and forecasts 2018 - 2030 (USD Million)
• 8.6. Service-based Model
  • 8.6.1. Market estimates and forecasts 2018 - 2030 (USD Million)
• 8.7. Pay Per Use Model
  • 8.7.1. Market estimates and forecasts 2018 - 2030 (USD Million)

Chapter 9. Biosimulation Market: End Use Estimates & Trend Analysis

• 9.1. Segment Dashboard
• 9.2. Global Biosimulation Market End Use Movement Analysis
• 9.3. Global Biosimulation Market Size & Trend Analysis, by End Use, 2018 - 2030 (USD Million)
• 9.4. Life Science Companies
  • 9.4.1. Market estimates and forecasts 2018 - 2030 (USD Million)
  • 9.4.2. Pharmaceutical Companies
    • 9.4.2.1. Market estimates and forecasts 2018 - 2030 (USD Million)
  • 9.4.3. Biopharma Companies
    • 9.4.3.1. Market estimates and forecasts 2018 - 2030 (USD Million)
  • 9.4.4. Medical Device Companies
    • 9.4.4.1. Market estimates and forecasts 2018 - 2030 (USD Million)
  • 9.4.5. CROs/CDMOs
    • 9.4.5.1. Market estimates and forecasts 2018 - 2030 (USD Million)
• 9.5. Academic Research Institutions
  • 9.5.1. Market estimates and forecasts 2018 - 2030 (USD Million)
• 9.6. Others (Regulatory Authorities, etc.)
  • 9.6.1. Market estimates and forecasts 2018 - 2030 (USD Million)

Chapter 10. Biosimulation Market: Regional Estimates & Trend Analysis

• 10.1. Regional Market Share Analysis, 2024 & 2030
• 10.2. Regional Market Dashboard
• 10.3. Market Size & Forecasts Trend Analysis, 2018 - 2030:
• 10.4. North America
  • 10.4.1. U.S.
    • 10.4.1.1. Key country dynamics
    • 10.4.1.2. Regulatory framework
    • 10.4.1.3. Competitive scenario
    • 10.4.1.4. U.S. market estimates and forecasts 2018 - 2030 (USD Million)
  • 10.4.2. Canada
    • 10.4.2.1. Key country dynamics
    • 10.4.2.2. Regulatory framework
    • 10.4.2.3. Competitive scenario
    • 10.4.2.4. Canada market estimates and forecasts 2018 - 2030 (USD Million)
  • 10.4.3. Mexico
    • 10.4.3.1. Key country dynamics
    • 10.4.3.2. Regulatory framework
    • 10.4.3.3. Competitive scenario
    • 10.4.3.4. Mexico market estimates and forecasts 2018 - 2030 (USD Million)
• 10.5. Europe
  • 10.5.1. UK
    • 10.5.1.1. Key country dynamics
    • 10.5.1.2. Regulatory framework
    • 10.5.1.3. Competitive scenario
    • 10.5.1.4. UK market estimates and forecasts 2018 - 2030 (USD Million)
  • 10.5.2. Germany
    • 10.5.2.1. Key country dynamics
    • 10.5.2.2. Regulatory framework
    • 10.5.2.3. Competitive scenario
    • 10.5.2.4. Germany market estimates and forecasts 2018 - 2030 (USD Million)
  • 10.5.3. France
    • 10.5.3.1. Key country dynamics
    • 10.5.3.2. Regulatory framework
    • 10.5.3.3. Competitive scenario
    • 10.5.3.4. France market estimates and forecasts 2018 - 2030 (USD Million)
  • 10.5.4. Italy
    • 10.5.4.1. Key country dynamics
    • 10.5.4.2. Regulatory framework
    • 10.5.4.3. Competitive scenario
    • 10.5.4.4. Italy market estimates and forecasts 2018 - 2030 (USD Million)
  • 10.5.5. Spain
    • 10.5.5.1. Key country dynamics
    • 10.5.5.2. Regulatory framework
    • 10.5.5.3. Competitive scenario
    • 10.5.5.4. Spain market estimates and forecasts 2018 - 2030 (USD Million)
  • 10.5.6. Norway
    • 10.5.6.1. Key country dynamics
    • 10.5.6.2. Regulatory framework
    • 10.5.6.3. Competitive scenario
    • 10.5.6.4. Norway market estimates and forecasts 2018 - 2030 (USD Million)
  • 10.5.7. Sweden
    • 10.5.7.1. Key country dynamics
    • 10.5.7.2. Regulatory framework
    • 10.5.7.3. Competitive scenario
    • 10.5.7.4. Sweden market estimates and forecasts 2018 - 2030 (USD Million)
  • 10.5.8. Denmark
    • 10.5.8.1. Key country dynamics
    • 10.5.8.2. Regulatory framework
    • 10.5.8.3. Competitive scenario
    • 10.5.8.4. Denmark market estimates and forecasts 2018 - 2030 (USD Million)
• 10.6. Asia Pacific
  • 10.6.1. Japan
    • 10.6.1.1. Key country dynamics
    • 10.6.1.2. Regulatory framework
    • 10.6.1.3. Competitive scenario
    • 10.6.1.4. Japan market estimates and forecasts 2018 - 2030 (USD Million)
  • 10.6.2. China
    • 10.6.2.1. Key country dynamics
    • 10.6.2.2. Regulatory framework
    • 10.6.2.3. Competitive scenario
    • 10.6.2.4. China market estimates and forecasts 2018 - 2030 (USD Million)
  • 10.6.3. India
    • 10.6.3.1. Key country dynamics
    • 10.6.3.2. Regulatory framework
    • 10.6.3.3. Competitive scenario
    • 10.6.3.4. India market estimates and forecasts 2018 - 2030 (USD Million)
  • 10.6.4. Australia
    • 10.6.4.1. Key country dynamics
    • 10.6.4.2. Regulatory framework
    • 10.6.4.3. Competitive scenario
    • 10.6.4.4. Australia market estimates and forecasts 2018 - 2030 (USD Million)
  • 10.6.5. South Korea
    • 10.6.5.1. Key country dynamics
    • 10.6.5.2. Regulatory framework
    • 10.6.5.3. Competitive scenario
    • 10.6.5.4. South Korea market estimates and forecasts 2018 - 2030 (USD Million)
  • 10.6.6. Thailand
    • 10.6.6.1. Key country dynamics
    • 10.6.6.2. Regulatory framework
    • 10.6.6.3. Competitive scenario
    • 10.6.6.4. Thailand market estimates and forecasts 2018 - 2030 (USD Million)
• 10.7. Latin America
  • 10.7.1. Brazil
    • 10.7.1.1. Key country dynamics
    • 10.7.1.2. Regulatory framework
    • 10.7.1.3. Competitive scenario
    • 10.7.1.4. Brazil market estimates and forecasts 2018 - 2030 (USD Million)
  • 10.7.2. Argentina
    • 10.7.2.1. Key country dynamics
    • 10.7.2.2. Regulatory framework
    • 10.7.2.3. Competitive scenario
    • 10.7.2.4. Argentina market estimates and forecasts 2018 - 2030 (USD Million)
• 10.8. MEA
  • 10.8.1. South Africa
    • 10.8.1.1. Key country dynamics
    • 10.8.1.2. Regulatory framework
    • 10.8.1.3. Competitive scenario
    • 10.8.1.4. South Africa market estimates and forecasts 2018 - 2030 (USD Million)
  • 10.8.2. Saudi Arabia
    • 10.8.2.1. Key country dynamics
    • 10.8.2.2. Regulatory framework
    • 10.8.2.3. Competitive scenario
    • 10.8.2.4. Saudi Arabia market estimates and forecasts 2018 - 2030 (USD Million)
  • 10.8.3. UAE
    • 10.8.3.1. Key country dynamics
    • 10.8.3.2. Regulatory framework
    • 10.8.3.3. Competitive scenario
    • 10.8.3.4. UAE market estimates and forecasts 2018 - 2030 (USD Million)
  • 10.8.4. Kuwait
    • 10.8.4.1. Key country dynamics
    • 10.8.4.2. Regulatory framework
    • 10.8.4.3. Competitive scenario
    • 10.8.4.4. Kuwait market estimates and forecasts 2018 - 2030 (USD Million)

Chapter 11. Competitive Landscape

• 11.1. Company/Competition Categorization
• 11.2. Strategy Mapping
• 11.3. Company Market Position/Share Analysis, 2024
• 11.4. Company Profiles/Listing
  • 11.4.1. Certara, USA
    • 11.4.1.1. Company overview
    • 11.4.1.2. Financial performance
    • 11.4.1.3. Product benchmarking
    • 11.4.1.4. Strategic initiatives
  • 11.4.2. Dassault Systemes
    • 11.4.2.1. Company overview
    • 11.4.2.2. Financial performance
    • 11.4.2.3. Product benchmarking
    • 11.4.2.4. Strategic initiatives
  • 11.4.3. Advanced Chemistry Development
    • 11.4.3.1. Company overview
    • 11.4.3.2. Financial performance
    • 11.4.3.3. Product benchmarking
    • 11.4.3.4. Strategic initiatives
  • 11.4.4. Simulation Plus
    • 11.4.4.1. Company overview
    • 11.4.4.2. Financial performance
    • 11.4.4.3. Product benchmarking
    • 11.4.4.4. Strategic initiatives
  • 11.4.5. Schrodinger, Inc.
    • 11.4.5.1. Company overview
    • 11.4.5.2. Financial performance
    • 11.4.5.3. Product benchmarking
    • 11.4.5.4. Strategic initiatives
  • 11.4.6. Chemical Computing Group ULC
    • 11.4.6.1. Company overview
    • 11.4.6.2. Financial performance
    • 11.4.6.3. Product benchmarking
    • 11.4.6.4. Strategic initiatives
  • 11.4.7. Physiomics Plc
    • 11.4.7.1. Company overview
    • 11.4.7.2. Financial performance
    • 11.4.7.3. Product benchmarking
    • 11.4.7.4. Strategic initiatives
  • 11.4.8. Rosa & Co. LLC
    • 11.4.8.1. Company overview
    • 11.4.8.2. Financial performance
    • 11.4.8.3. Product benchmarking
    • 11.4.8.4. Strategic initiatives
  • 11.4.9. BioSimulation Consulting Inc.
    • 11.4.9.1. Company overview
    • 11.4.9.2. Financial performance
    • 11.4.9.3. Product benchmarking
    • 11.4.9.4. Strategic initiatives
  • 11.4.10. Genedata AG
    • 11.4.10.1. Company overview
    • 11.4.10.2. Financial performance
    • 11.4.10.3. Product benchmarking
    • 11.4.10.4. Strategic initiatives
  • 11.4.11. Instem Group of Companies
    • 11.4.11.1. Company overview
    • 11.4.11.2. Financial performance
    • 11.4.11.3. Product benchmarking
    • 11.4.11.4. Strategic initiatives
  • 11.4.12. PPD, Inc.
    • 11.4.12.1. Company overview
    • 11.4.12.2. Financial performance
    • 11.4.12.3. Product benchmarking
    • 11.4.12.4. Strategic initiatives
  • 11.4.13. Yokogawa Insilico Biotechnology GmbH
    • 11.4.13.1. Company overview
    • 11.4.13.2. Financial performance
    • 11.4.13.3. Product benchmarking
    • 11.4.13.4. Strategic initiatives